Singlera Genomics Incorporated

Singlera Genomics Incorporated is a biotechnology startup based in the United States, founded in 2014. The company focuses on developing 'liquid biopsy'​ analysis reagents and software, specifically targeting the detection of cancer at earlier stages through the power of circulating tumor methylated DNA (ctmDNA). Singlera's PanSeer assay, backed by a CNY300.00M Series B investment at 08 June 2022 from investors including Junci Investment, FutureX Capital, Venture capitalist, China Galaxy Securities, Sansure Biotech, Best, is capable of identifying cancer up to four years before conventional diagnosis. This revolutionary technology boasts high sensitivity and specificity, with the ColonES assay demonstrating over 97% sensitivity for CRC Stg I and 91% for advanced adenomas, as well as 99% specificity for healthy individuals. Singlera is currently gearing up for commercialization and seeking potential collaborators to bring its groundbreaking technology to the market.